We and others have shown that IRF4 promotes proliferation of EBV-transformed cells and IRF4 deficiency results in death of cells derived from different hematological malignancies [17], [28], [35], indicating that IRF4 plays a non-redundant role in tumorigenesis of hematological malignancies. This evidence concerns the gene IRF4 and hematologic disorder.